177 related articles for article (PubMed ID: 36104447)
1. Determination of pharmacokinetics and tissue distribution of a novel lutetium-labeled PSMA-targeted ligand,
Song CH; Kim K; Kang E; Jeong B; Lee MS; Jung J; Kim TH; Shin S; Shin BS
Sci Rep; 2022 Sep; 12(1):15452. PubMed ID: 36104447
[TBL] [Abstract][Full Text] [Related]
2. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
Escudero-Castellanos A; Ocampo-García B; Ferro-Flores G; Santos-Cuevas C; Morales-Ávila E; Luna-Gutiérrez M; Isaac-Olivé K
Nucl Med Commun; 2019 Mar; 40(3):278-286. PubMed ID: 30763290
[TBL] [Abstract][Full Text] [Related]
4.
Dai R; Cai Z; Hu R; Huang Y; Fu L; Yang J; Hu K; Li H
Mol Pharm; 2024 Feb; 21(2):883-894. PubMed ID: 38155100
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeling of PSMA-617 with
Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y
Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro evaluation of
Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
[TBL] [Abstract][Full Text] [Related]
7. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.
Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S
Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032
[TBL] [Abstract][Full Text] [Related]
8.
Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of
Vaughn BA; Loveless CS; Cingoranelli SJ; Schlyer D; Lapi SE; Boros E
Mol Pharm; 2021 Dec; 18(12):4511-4519. PubMed ID: 34714082
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
12. Preparation of
Guleria M; Amirdhanayagam J; Sarma HD; Rallapeta RP; Krishnamohan VS; Nimmagadda A; Ravi P; Patri S; Kalawat T; Das T
Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436
[TBL] [Abstract][Full Text] [Related]
13. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
14. Inductively Coupled Plasma Mass Spectrometry─A Valid Method for the Characterization of Metal Conjugates in View of the Development of Radiopharmaceuticals.
Wallimann RH; Schindler P; Hensinger H; Tschan VJ; Busslinger SD; Kneuer R; Müller C; Schibli R
Mol Pharm; 2023 Apr; 20(4):2150-2158. PubMed ID: 36826437
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
[TBL] [Abstract][Full Text] [Related]
17. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Ruigrok EAM; Tamborino G; de Blois E; Roobol SJ; Verkaik N; De Saint-Hubert M; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3627-3638. PubMed ID: 35556158
[TBL] [Abstract][Full Text] [Related]
18. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
20. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
Keam SJ
Mol Diagn Ther; 2022 Jul; 26(4):467-475. PubMed ID: 35553387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]